Yaghoobi Mohammad, Mehraban Far Parsa, Mbuagbaw Lawrence, Yuan Yuhong, Armstrong David, Thabane Lehana, Moayyedi Paul
Division of Gastroenterology, McMaster University, Hamilton, Ontario, Canada.
Department of Health Research Methods, Evidence, and Impact (HEI), McMaster University, Hamilton, Ontario, Canada.
Middle East J Dig Dis. 2022 Oct;14(4):382-395. doi: 10.34172/mejdd.2022.299. Epub 2022 Oct 30.
: Fecal immunoglobulin test (FIT) has been advocated as the first line of screening for colorectal cancer (CRC) in several jurisdictions. Most studies have focused on CRC as the outcome of interest. Our goal was to quantify the diagnostic accuracy of different thresholds of FIT as compared with colonoscopy for detection of advanced colonic neoplasia and potential modifiers using proper Cochrane methodology. : A comprehensive electronic search was performed for studies on FIT using colonoscopy as the reference standard to detect advanced neoplasia. Cochrane methodology was used to perform a diagnostic test accuracy (DTA) meta-analysis. Diagnostic accuracy of different cut-offs of FIT, including 25, 50, 75, 100, 150, and 200 ng/mL, were calculated separately. Meta-regression analysis was also performed to detect potential modifiers, including age, location of the tumor, and time from FIT to colonoscopy. : Twenty-four studies were included with no evidence of publication bias. The sensitivity of FIT did not decrease with lowering the cut-off, although specificity increased in higher cut-offs. Commonly used cut-offs of 50 ng/mL, 75 ng/mL, and 100 ng/mL for FIT provided sensitivity of 39%, 36%, 27% and specificity of 92%, 94%, 96%, respectively. Diagnostic accuracy of FIT did not significantly differ in proximal versus distal lesions or in individuals below or over the age of 50 years. The results remained robust in a meta-regression of the location of the study, time from FIT to colonoscopy, and methodological quality. : The sensitivity of FIT might have been overestimated in previous studies focusing on CRC, and it seems to be independent of age, location of neoplasia, or cut-offs, contrary to some previous studies. Lowering the cut-off will reduce the diagnostic odds ratio (DOR) by increasing specificity but without any effect on sensitivity.
粪便免疫球蛋白检测(FIT)在多个司法管辖区被倡导作为结直肠癌(CRC)筛查的一线方法。大多数研究将CRC作为关注的结果。我们的目标是使用适当的Cochrane方法,量化与结肠镜检查相比,不同FIT阈值检测晚期结肠肿瘤及潜在影响因素的诊断准确性。
对以结肠镜检查作为检测晚期肿瘤参考标准的FIT研究进行了全面的电子检索。使用Cochrane方法进行诊断试验准确性(DTA)荟萃分析。分别计算了FIT不同临界值(包括25、50、75、100、150和200 ng/mL)的诊断准确性。还进行了荟萃回归分析以检测潜在的影响因素,包括年龄、肿瘤位置以及从FIT到结肠镜检查的时间。
纳入了24项研究,无发表偏倚的证据。FIT的敏感性不会随着临界值降低而下降,尽管较高临界值时特异性增加。FIT常用的50 ng/mL、75 ng/mL和100 ng/mL临界值的敏感性分别为39%、36%、27%,特异性分别为92%、94%、96%。FIT在近端与远端病变或50岁以下与50岁以上个体中的诊断准确性无显著差异。在对研究地点、从FIT到结肠镜检查的时间以及方法学质量进行的荟萃回归分析中,结果仍然稳健。
在先前关注CRC的研究中,FIT的敏感性可能被高估了,并且与一些先前的研究相反,它似乎与年龄、肿瘤位置或临界值无关。降低临界值会通过增加特异性来降低诊断比值比(DOR),但对敏感性没有任何影响。